Predicting response to immunosuppressive therapy in childhood aplastic anemia

Haematologica

Volumn 96, Issue 5, 2011, Pages 771-774

  Yoshida, Nao ^a   Yagasaki, Hiroshi ^b   Hama, Asahito ^c   Takahashi, Yoshiyuki ^c   Kosaka, Yoshiyuki ^d   Kobayashi, Ryoji ^e   Yabe, Hiromasa ^f   Kaneko, Takashi ^g   Tsuchida, Masahiro ^h   Ohara, Akira ⁱ   Nakahata, Tatsutoshi ^j   Kojima, Seiji ^c  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Hyogo Children's Hospital   (Japan)

^e SAPPORO HOKUYU HOSPITAL   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Tokyo Metropolitan Kiyose Children's Hospital   (Japan)

^h Ibaraki Children's Hospital   (Japan)

ⁱ TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Aplastic anemia; Children; Immunosuppressive therapy; Predictive marker

Indexed keywords

CYCLOSPORIN; LYMPHOCYTE ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ASSESSMENT; COHORT ANALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT RESPONSE;

ADOLESCENT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKOCYTE COUNT; MALE; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955770735     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.032805     Document Type: Article

References (23)

1. Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000;111(1):321-8.
2. Mathe G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Transplant Proc. 1971;3(1):325-32.
3. Young NS. Acquired aplastic anemia. JAMA. 1999;282(3):271-8.
4. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85(5):1348-53.
5. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106 (6):2102-4.
6. Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96 (6):2049-54.
7. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-8.
8. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289 (9):1130-5.
9. Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S, Matsuda T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84(12):4257-61.
10. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98(13):3513-9.
11. Oguz FS, Yalman N, Diler AS, Oguz R, Anak S, Dorak MT. HLA-DRB1 15 and pediatric aplastic anemia. Haematologica. 2002;87(7):772-4.
12. Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria- type cells, and an aplastic anaemiaassociated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008;142(3):427-35.
13. Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2009;84(2):154-9.
14. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814-9.
15. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206-16.
16. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53(3): 504-14.
17. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054-9.
18. Nissen C, Gratwohl A, Tichelli A, Stebler C, Wursch A, Moser Y, et al. Gender and response to antilymphocyte globulin (ALG) for severe aplastic anaemia. Br J Haematol. 1993;83(2):319-25.
19. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177-82.
20. Hinterberger W, Adolf G, Aichinger G, Dudczak R, Geissler K, Hocker P, et al. Further evidence for lymphokine overproduction in severe aplastic anemia. Blood. 1988;72(1):266-72.
21. Hoffman R, Zanjani ED, Lutton JD, Zalusky R, Wasserman LR. Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia. N Engl J Med. 1977;296(1):10-3.
22. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA. 1985;82(1):188-92.
23. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta- CDR3 sequencing. Lancet. 2004;364(9431): 355-64.